3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Melanoma
16
Triple Negative Breast Neoplasms
13
Colorectal Neoplasms
11
Neoplasms
9
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
7
Pancreatic Neoplasms
7
Carcinoma, Renal Cell
7
Stomach Neoplasms
6
Lymphoma
6
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Lung Neoplasms
4
Liver Neoplasms
4
Head and Neck Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Nasopharyngeal Carcinoma
3
Colonic Neoplasms
3
Carcinoma, Hepatocellular
3
Advanced Solid Tumor
3
Solid Tumors
2
Solid Tumor, Adult
2
Recurrence
2
Rectal Neoplasms
2
Interventions
pembrolizumab
15
Nivolumab
10
Ipilimumab
7
cemiplimab
6
dabrafenib
4
binimetinib
4
Dacarbazine
4
trametinib
3
encorafenib
3
Drug Therapy
3
Allovectin-7
3
zanolimumab
2
talabostat
2
lifileucel
2
aldesleukin
2
Vemurafenib
2
Tablets
2
Semaxinib
2
Intravital Microscopy
2
Interleukin-2
2
Fluorouracil
2
vitespin
1
veliparib
1
varlilumab
1
tozuleristide
1
tin etiopurpurin
1
tilsotolimod
1
spartalizumab
1
sotigalimab
1
sonidegib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Skin Neoplasms
×
spartalizumab
×
Clear all
NCT02967692
2025-09-18
COMBI-i
Novartis
Phase 3
Terminated
568 enrolled
28 charts